Vaccinex, Inc.

NasdaqCM VCNX

Vaccinex, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024

Vaccinex, Inc. Net Income is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Vaccinex, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -21.99 M, a -13.63% change year over year.
Vaccinex, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -19.35 M, a 20.02% change year over year.
Vaccinex, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -24.19 M, a 15.79% change year over year.
Vaccinex, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -28.73 M, a 15.47% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: VCNX

Vaccinex, Inc.

CEO	Dr. Maurice Zauderer Ph.D.
IPO Date	Aug. 9, 2018
Location	United States
Headquarters	1895 Mount Hope Avenue
Employees	37
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Key trends

Past 5 years